KR20250002778A - Glp1 제약 조성물 - Google Patents
Glp1 제약 조성물 Download PDFInfo
- Publication number
- KR20250002778A KR20250002778A KR1020247040462A KR20247040462A KR20250002778A KR 20250002778 A KR20250002778 A KR 20250002778A KR 1020247040462 A KR1020247040462 A KR 1020247040462A KR 20247040462 A KR20247040462 A KR 20247040462A KR 20250002778 A KR20250002778 A KR 20250002778A
- Authority
- KR
- South Korea
- Prior art keywords
- fluoro
- composition
- amount
- methylcyclopropyl
- oxadiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340591P | 2022-05-11 | 2022-05-11 | |
| US63/340,591 | 2022-05-11 | ||
| PCT/US2023/021637 WO2023220109A1 (en) | 2022-05-11 | 2023-05-10 | Glp1 pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250002778A true KR20250002778A (ko) | 2025-01-07 |
Family
ID=86732348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247040462A Pending KR20250002778A (ko) | 2022-05-11 | 2023-05-10 | Glp1 제약 조성물 |
Country Status (17)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20250009A1 (es) * | 2022-05-11 | 2025-01-07 | Lilly Co Eli | Composiciones de comprimidos de glp1 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| KR20260118441A (ko) * | 2023-11-21 | 2026-07-30 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용 |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| CA2434641A1 (en) * | 2001-01-18 | 2002-08-22 | Pharmacia And Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| AU2007293032A1 (en) * | 2006-09-08 | 2008-03-13 | Merck Sharp & Dohme Corp. | Liquid pharmaceutical formulations for oral administration of a CGRP antagonist |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| PL3984523T3 (pl) * | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| US11884672B2 (en) * | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| JP7796115B2 (ja) * | 2020-09-09 | 2026-01-08 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチン調節因子の製剤 |
| PE20250009A1 (es) * | 2022-05-11 | 2025-01-07 | Lilly Co Eli | Composiciones de comprimidos de glp1 |
-
2023
- 2023-05-10 EP EP23729579.5A patent/EP4522129A1/en active Pending
- 2023-05-10 JP JP2024566219A patent/JP7767651B2/ja active Active
- 2023-05-10 AU AU2023269995A patent/AU2023269995A1/en active Pending
- 2023-05-10 CA CA3253043A patent/CA3253043A1/en active Pending
- 2023-05-10 US US18/864,210 patent/US20250302809A1/en active Pending
- 2023-05-10 PE PE2025002371A patent/PE20260136A1/es unknown
- 2023-05-10 WO PCT/US2023/021637 patent/WO2023220109A1/en not_active Ceased
- 2023-05-10 KR KR1020247040462A patent/KR20250002778A/ko active Pending
- 2023-05-10 PE PE2024002463A patent/PE20251285A1/es unknown
- 2023-05-10 IL IL316629A patent/IL316629A/en unknown
- 2023-05-10 CN CN202380039380.7A patent/CN119173255A/zh active Pending
- 2023-05-11 TW TW113144409A patent/TW202508581A/zh unknown
- 2023-05-11 AR ARP230101165A patent/AR129296A1/es unknown
- 2023-05-11 TW TW112117510A patent/TWI867526B/zh active
-
2024
- 2024-11-05 JO JOJO/P/2024/0245A patent/JOP20240245A1/ar unknown
- 2024-11-06 CL CL2024003392A patent/CL2024003392A1/es unknown
- 2024-11-08 MX MX2024013839A patent/MX2024013839A/es unknown
- 2024-11-08 CO CONC2024/0015285A patent/CO2024015285A2/es unknown
- 2024-11-11 DO DO2024000232A patent/DOP2024000232A/es unknown
-
2025
- 2025-10-29 JP JP2025182180A patent/JP2026021422A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI867526B (zh) | 2024-12-21 |
| JOP20240245A1 (ar) | 2024-11-05 |
| TW202508581A (zh) | 2025-03-01 |
| PE20251285A1 (es) | 2025-05-14 |
| IL316629A (en) | 2024-12-01 |
| WO2023220109A1 (en) | 2023-11-16 |
| MX2024013839A (es) | 2024-12-06 |
| CA3253043A1 (en) | 2023-11-16 |
| JP2026021422A (ja) | 2026-02-10 |
| CL2024003392A1 (es) | 2025-03-14 |
| AR129296A1 (es) | 2024-08-07 |
| TW202410894A (zh) | 2024-03-16 |
| CN119173255A (zh) | 2024-12-20 |
| PE20260136A1 (es) | 2026-01-21 |
| AU2023269995A1 (en) | 2024-11-14 |
| US20250302809A1 (en) | 2025-10-02 |
| DOP2024000232A (es) | 2024-12-30 |
| JP7767651B2 (ja) | 2025-11-11 |
| EP4522129A1 (en) | 2025-03-19 |
| JP2025515706A (ja) | 2025-05-20 |
| CO2024015285A2 (es) | 2024-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7767651B2 (ja) | Ｇｌｐ１医薬組成物 | |
| JP4780522B2 (ja) | フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤 | |
| JP5794650B2 (ja) | 難溶性薬物の溶解性改善製剤 | |
| US10098843B2 (en) | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine | |
| JP2010509289A (ja) | チロシンキナーゼ阻害剤の経口投与用薬学的剤形 | |
| US20110136883A1 (en) | Granulation of active pharmaceutical ingredients | |
| TW201446286A (zh) | 抗病毒化合物之固態分散調製劑 | |
| JP2015503612A (ja) | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 | |
| WO2023220112A1 (en) | Glp1 tablet compositions | |
| US20070248682A1 (en) | Solid preparation comprising enteric solid dispersion | |
| JP7322475B2 (ja) | アジルサルタンを含有する錠剤 | |
| JP3037393B2 (ja) | 経口投与用固形薬剤の製造方法 | |
| EP2219614A1 (en) | Pharmaceutical composition of orlistat | |
| EP2153822A1 (en) | Granulation of active pharmaceutical ingredients | |
| JP6903252B2 (ja) | キサンチンオキシダーゼ阻害剤含有腸溶性製剤 | |
| CN118304306A (zh) | 无定形固体分散体、药物组合物及制备方法和应用 | |
| SI22571A (sl) | Stabilen trden farmacevtski sestavek, ki obsega kandesartan ali njegove farmacevtsko sprejemljive oblike |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20241205 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20241205 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application |